| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Sarafotoxin C targets the endothelin-B (ETB) receptor, a G-protein coupled receptor expressed on vascular smooth muscle cells and endothelial cells. It shows minimal activity at the endothelin-A (ETA) receptor, with approximately 100,000-fold selectivity for ETB over ETA. ETB receptors mediate vasodilation via nitric oxide release and vasoconstriction via smooth muscle contraction.
|
|---|---|
| ln Vitro |
In vitro, Sarafotoxin C causes contraction of both endothelium-intact and endothelium-denuded vessels. It binds to the ETB receptor on vascular smooth muscle cells, triggering phospholipase C activation and subsequent intracellular calcium mobilization. The peptide is used to study endothelin receptor pharmacology and vascular function.
|
| ln Vivo |
Both endothelial-denuded and endothelial-intact arteries may constrict as a result of sarafotoxin S6c [1].
In vivo, Sarafotoxin C causes vasoconstriction and increases arterial pressure in animal models. It has been studied in the context of pulmonary hypertension, particularly in rat models of chronic hypoxia. The peptide's effects on vascular tone make it valuable for cardiovascular research. |
| Enzyme Assay |
Receptor binding assays for Sarafotoxin C utilize membrane preparations from cells expressing ETB or ETA receptors. Radiolabeled endothelin-1 or sarafotoxin is incubated with varying concentrations of the test peptide, and binding affinity is determined by competition binding curves.
|
| Cell Assay |
Cell-based assays for Sarafotoxin C typically use vascular smooth muscle cell cultures. Cells are treated with the peptide, and intracellular calcium levels are measured using fluorescent indicators such as Fura-2. Phospholipase C activation and downstream signaling pathways can also be assessed.
|
| Animal Protocol |
Animal/Disease Models: Male Wister rats, exposed to 10% O2 [chronic hypoxic (CH) rats] or room air (control rats) for 2 weeks [1]
Doses: 1 pM-1 mM Route of Administration: Experimental Results: Chronic Both the sensitivity of the main pulmonary artery to SCS6c and the small vasoconstrictive response to hypoxia were evident. Produces vasoconstriction in both endothelially intact and endothelially stripped vessels, with a maximum response of 30% of ET-1. In vivo studies with Sarafotoxin C are conducted in rodent models, including chronic hypoxic rats. The peptide is administered via intravenous injection, and hemodynamic parameters such as arterial pressure and vascular resistance are monitored. Effects on pulmonary vasculature are of particular interest. |
| ADME/Pharmacokinetics |
As a peptide, Sarafotoxin C is expected to have a short half-life due to proteolytic degradation. The compound should be stored at -20degC. It is soluble in acetonitrile and water. Standard peptide handling and storage procedures apply.
|
| Toxicity/Toxicokinetics |
Toxicity data for Sarafotoxin C are limited. As a snake venom-derived peptide, it has potent biological activity at very low concentrations and should be handled with care. Appropriate safety precautions, including the use of personal protective equipment, are recommended.
|
| References | |
| Additional Infomation |
Sarafotoxin C is a research-use peptide and is not approved for therapeutic applications. It is also known as Sarafotoxin S6c and SRTX-c. The sequence is CTCNDMTDEECLNFCHQDVIW with disulfide bridges between Cys1-Cys15 and Cys3-Cys11. The molecular formula is C103H14₇N2₇O3₇S₅ and molecular weight is 2515.75.
|
| Molecular Formula |
C103H147N27O37S5
|
|---|---|
| Molecular Weight |
2515.75298
|
| Exact Mass |
2513.91
|
| CAS # |
121695-87-2
|
| PubChem CID |
16132429
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
34
|
| Hydrogen Bond Acceptor Count |
44
|
| Rotatable Bond Count |
48
|
| Heavy Atom Count |
172
|
| Complexity |
5630
|
| Defined Atom Stereocenter Count |
0
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3975 mL | 1.9875 mL | 3.9750 mL | |
| 5 mM | 0.0795 mL | 0.3975 mL | 0.7950 mL | |
| 10 mM | 0.0397 mL | 0.1987 mL | 0.3975 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
